Compare NABL & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NABL | MRVI |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 825.1M | 1.0B |
| IPO Year | 2021 | 2020 |
| Metric | NABL | MRVI |
|---|---|---|
| Price | $4.37 | $6.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $8.31 | $4.13 |
| AVG Volume (30 Days) | 1.9M | ★ 3.0M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $511,430,000.00 | $185,743,000.00 |
| Revenue This Year | $11.04 | $12.54 |
| Revenue Next Year | $8.53 | $7.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 9.71 | N/A |
| 52 Week Low | $2.92 | $1.99 |
| 52 Week High | $9.04 | $7.44 |
| Indicator | NABL | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 55.66 | 60.17 |
| Support Level | $4.15 | $5.67 |
| Resistance Level | $5.22 | N/A |
| Average True Range (ATR) | 0.32 | 0.36 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 55.57 | 57.91 |
N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. The company also has a presence in the United Kingdom and all other International regions.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.